Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Clavis Pharma General Information
Developed novel anti-cancer drugs using Lipid Vector Technology to improve efficacy and reduce side effects of established drugs. Lead product elacytarabine showed promising survival data in late-stage acute myeloid leukemia.
Contact Information
Drug Pipeline
elacytarabine
Phase 3Key Partnerships
Clovis Oncology ($380 million partnership in 2009, expanded to $205 million global rights deal in 2010), Translational Therapeutics, Inc., Mount Sinai School of Medicine
Clavis Pharma Funding
No funding data available
To view Clavis Pharma's complete valuation and funding history, request access »